ArticleOncogene2018
IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
Open access · greenAbstract read
In one paragraph
Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.Nature communications · 2026Article
- Article
- Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancer.Cell communication and signaling : CCS · 2025Article
- Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.Breast cancer research : BCR · 2023Article
- SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer.Cancers · 2023Article
- Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity.Biomedicines · 2023Review
- Circular RNA 0001789 sponges miR-140-3p and regulates PAK2 to promote the progression of gastric cancer.Journal of translational medicine · 2023Article
- Drugging IGF-1R in cancer: New insights and emerging opportunities.Genes & diseases · 2023Review
- Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer.Cancer biology & therapy · 2022Article
- Article
- Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer.Journal of clinical medicine · 2022Article
- GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer.NPJ breast cancer · 2022Article
- Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Review
- IGF1R signalling is a guardian of self-tolerance restricting autoantibody production.Frontiers in immunology · 2022Article
- Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis.Discover oncology · 2021Article
- TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Effects of Txk‑mediated activation of NF‑κB signaling pathway on neurological deficit and oxidative stress after ischemia‑reperfusion in rats.Molecular medicine reports · 2021Article
- Protein co-expression networks identified from HOT lesions of ER+HER2-Ki-67high luminal breast carcinomas.Scientific reports · 2021Article
- hsa_circ_0013401 Accelerates the Growth and Metastasis and Prevents Apoptosis and Autophagy of Neuroblastoma Cells by Sponging miR-195 to Release PAK2.Oxidative medicine and cellular longevity · 2021Article
- ERα is a target for butein-induced growth suppression in breast cancer.American journal of cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Yinghui ZhangDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. y.zhang@lacdr.leidenuniv.nl.
Lynn WesterDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Jichao HeDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Tamar GeigerDepartment of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Marja MoerkensDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Ram SiddappaDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Jean A HelmijrDepartment of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
Mieke M TimmermansDepartment of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
Maxime P LookDepartment of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
Caroline H M van DeurzenDepartment of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
John W M MartensDepartment of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.ORCID 0000-0002-3428-3366
Chantal PontDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Marjo de GraauwDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Erik H J DanenDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Els M J J BernsDepartment of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
John H N MeermanDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Maurice P H M JansenDepartment of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
Bob van de WaterDivision of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. b.water@lacdr.leidenuniv.nl.
Leiden University · NLCancer Genomics Centre · NLErasmus MC · NLTel Aviv University · IL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiestrogen resistance in estrogen receptor positive (ER
Indexed as
Antineoplastic Agents, HormonalBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmEstrogen AntagonistsFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHEK293 CellsHigh-Throughput Screening AssaysHumansMCF-7 Cellsp21-Activated KinasesReceptor, IGF Type 1Receptors, SomatomedinRho Guanine Nucleotide Exchange FactorsAntineoplastic Agents, HormonalEstrogen AntagonistsIGF1R protein, humanp21-Activated KinasesPAK2 protein, humanPIX protein, humanReceptor, IGF Type 1Receptors, SomatomedinRho Guanine Nucleotide Exchange FactorsRNA, Small InterferingTamoxifen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.